.jpg)
.png)
Following the Foundation of the NLA’s inaugural Familial Hypercholesterolemia Roundtable in New Orleans this past February, I am pleased to report meaningful progress on our important FH initiative.
Article By:
President, Foundation of the National Lipid Association
Associate Professor of Medicine
Washington University School of Medicine
St. Louis, MO
Diplomate, American Board of Clinical Lipidology
Like many young clinicians starting out, Daniel Steinberg, MD, PhD, did not intend to build a career in Clinical Lipidology. But the Harvard-trained biochemist had motivation to pick a field quickly: it was 1950, the Korean War had just broken out, and he had served less than two years in World War II. His thesis supervisor, Christian B. Anfinsen, MD, had just accepted a position at what was the newly created National Heart Institute-if Dr.
Article By:
University of California-San Diego
La Jolla, CA
Diplomate, American Board of Clinical Lipidology
As President-elect of the Pacific Lipid Association, it gives me a great pleasure to present our chapter update. Our members continue to be very active in their communities as well as throughout the NLA. Our own Matthew Ito, PharmD, will become the NLA President this May.
Article By:
President-elect, Pacific Lipid Association
Northern Nevada Lipidology
Carson City, NV
Diplomate, American Board of Clinical Lipidology
R.E. is a 58-year-old Asian male who finally quit smoking one month ago, and is now being treated for hypertension to goal with the combination amlodipine/benazepril. He has type 2 diabetes and takes metformin 500 mg bid. His initial lipid panel revealed a TC=230 mg/dL, LDL=140 mg/dL, HDL=35 mg/dL and TG=265mg/dL and his Non HDL- was 195. His BMI was 29, FBS=109mg/dL and his HbA1C=6.8. In general he has led a sedentary lifestyle.
Article By:
California Heart Associates
Clinical Assistant Professor, UC-Irvine Medical Center
Orange County, CA
Diplomate, American Board of Clinical Lipidology
Preventive Cardiology Center
Santa Monica, CA
It is typically silent, but sometimes you can hear it, a soft systolic ejection murmur heard over the aortic area during cardiac auscultation on physical examination. As cardiovascular risk reduction specialists, we do not to want to miss this cardiac murmur. It is not innocent or benign; this is the murmur of aortic valve sclerosis (ASc).
Article By:
Pacific Lipid Association President
Director, Preventive Cardiology and Cardiovascular Rehabilitation
Director, Lipid Clinic and LDL Apheresis Program
Chair, Department of Cardiology
Saint Alphonsus Regional Medical Center
Boise, ID
Diplomate, American Board of Clinical Lipidology
Pacific Lipid Association Immediate Past President
Director, California Cardiovascular Institute
Assistant Clinical Professor, UCSF School of Medicine
Fresno Medicine Residency Program-Volunteer
Fresno, CA
Diplomate, American Board of Clinical Lipidology
Coronary heart disease (CHD) remains the leading cause of death in Western civilizations. The role of abnormal lipid metabolism as a modifiable risk factor for CHD is well documented. The presence of chronic kidney disease (CKD) is also associated with an increased risk of CHD, but the pathogenesis of this relationship is not completely understood.
Article By:
Department of Medicine
University of Nevada School of Medicine
Reno, NV
Diplomate, American Board of Clinical Lipidology
Division of Nephrology, Hypertension and Transplantation
Oregon State University and Oregon Health and Science University
Portland, OR
Lipoprotein(a), also referred to as Lp(a), is an unusual plasma lipoprotein that was first described by Berg in 1963.1 The lipoprotein(a) particle consists of a low density lipoprotein (LDL) particle to which a single molecule of apoprotein(a) is covalently bound via a disulfide linkage to apoprotein B-100. The size of the apoprotein(a) moiety varies substantially between individuals because of differences in the number of kringle-4 repeats, as discussed below.
Article By:
Director, Lipid Disorders Clinic and Lipid-Atherosclerosis Laboratory
Oregon Health and Science University
Portland, OR
Recent high-profile interventional studies and a large genetic association analysis have failed to show a benefit of raising high density lipoprotein cholesterol (HDL-C) levels on cardiovascular disease (CVD) outcomes, calling into question the validity of the HDL hypothesis. Among several plausible explanations for these findings, one is that assaying the cholesterol content of HDL (HDL-C) may fail to adequately measure its protective effects.
Article By:
Assistant Professor of Medicine and Radiology
Knight Cardiovascular Institute
Oregon Health & Science University
Director, Preventive Cardiology and Atherosclerosis Imaging
Diplomate, American Board of Clinical Lipidology
Director, Atherometabolic Research
Utah Foundation for Biomedical Research
Salt Lake City, UT
Diplomate, American Board of Clinical Lipidology
Remnant Lipoproteins Promote Foam Cell Formation
Article By:
Pacific Lipid Association Immediate Past President
Director, California Cardiovascular Institute
Assistant Clinical Professor, UCSF School of Medicine
Fresno Medicine Residency Program-Volunteer
Fresno, CA
Diplomate, American Board of Clinical Lipidology
Professor of Internal Medicine
University of Utah
Co-Director, Cardiovascular Disease Risk Reduction Clinic
Salt Lake City, UT
Diplomate, American Board of Clinical Lipidology
The year 2013 marks the "Silver Anniversary" of three key announcements that identified relationships among various lipid fractions, lipoproteins, apolipoproteins, non-lipid disorders and cardiovascular disease (CVD) risk.
Article By:
Director, Diabetes/Lipid Management & Research Center, Huntington Beach, CA
Clinical Professor, Dept. of Medicine, Division Endocrinology/Diabetes/Metabolism,
University of California, Irvine (UCI) School of Medicine, Irvine, CA
Co-Director, Diabetes Out-Patient Clinic, UCI Medical Center, Orange, CA
Diplomate, American Board of Clinical Lipidology
Professor of Medicine, Department of Medicine, Division of Cardiology
Adjunct Professor of Radiology, Director of Echocardiography
Harborview Medical Center, University of Washington
Clinical Professor of Diagnostic Ultrasound
Seattle University
Seattle, WA
Diplomate, American Board of Clinical Lipidology
Swedish Hospital Medical Center
Seattle, WA
Diplomate, American Board of Clinical Lipidology